Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice

Neuroendocrinology

Volumn 82, Issue 3-4, 2005, Pages 171-176

  Johanson, Viktor ^a   Arvidsson, Yvonne ^a   Kölby, Lars ^a   Bernhardt, Peter ^a   Swärd, Christina ^a   Nilsson, Ola ^a   Ahlman, Håkan ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 hydroxyindole acetic acid; Anticancer drug; BON cells; Medullary thyroid carcinoma; Midgut carcinoid; Neuroendocrine tumour; Nude mice; Pyridyl cyanoguanidine; Xenotransplants

Indexed keywords

ANTINEOPLASTIC AGENT; GUANIDINE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (6 CHLOROPHENOXYHEXYL) N' CYANO N' 4 PYRIDYLGUANIDINE; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; NITRILE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOID; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; INTESTINE TUMOR; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; NUDE MOUSE; PANCREAS TUMOR; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYANIDES; FEMALE; GUANIDINES; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEUROENDOCRINE TUMORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33646527980     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091754     Document Type: Article

References (21)

1. Karin M, Yamamoto Y, Wang QM: The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
2. Hjarnaa PJ, Jonsson E, Latini S, Dhar S, Larsson R, Bramm E, Skov T, Binderup L: CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res 1999;59:5751-5757.
3. Aleskog A, Bashir-Hassan S, Hovstadius P, Kristensen J, Höglund M, Tholander B, Binderup L, Larsson R, Jonsson E: Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro. Anticancer Drugs 2001;12:821-827.
4. Svensson A, Backman U, Jonsson E, Larsson R, Christofferson R: CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs. Pediatr Res 2002;51:607-611.
5. Wojciechowski J, Lövborg H, Wesierska-Gadek J: Activation of p53 protein in normal and in tumor cells by a novel anticancer agent CHS 828. Drugs Exp Clin Res 2003;29:53-67.
6. Hovstadius P, Lindhagen E, Hassan S, Nilsson K, Jernberg-Wiklund H, Nygren P, Binderup L, Larsson R: Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines. Anticancer Drugs 2004;15:63-70.
7. Olsen LS, Hjarnaa PJ, Latini S, Holm PK, Larsson R, Bramm E, Binderup L, Madsen MW: Anticancer agent CHS 828 suppresses nuclear factor-κB activity in cancer cells through downregulation of IKK activity. Int J Cancer 2004;111:198-205.
8. Ludwig L, Kessler H, Wagner M, Hoang-Vu C, Dralle H, Adler G, Bohm BO, Schmid RM: Nuclear factor-κB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res 2001;61:4526-4535.
9. Ravaud A, Cerny T, Terret C, Wanders J, Bui BN, Hess D, Droz JP, Fumoleau P, Twelves C: Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 2005;41:702-707.
10. Kölby L, Bernhardt P, Ahlman H, Wängberg B, Johanson V, Wigander A, Forssell-Aronsson E, Karlsson S, Ahren B, Stenman G, Nilsson O: A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol 2001;158:745-755.
11. Evers BM, Townsend CM Jr, Upp JR, Allen E, Hurlbut SC, Kim SW, Rajaraman S, Singh P, Reubi JC, Thompson JC: Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology 1991;101:303-311.
12. Johanson V, Ahlman H, Bernhardt P, Jansson S, Kölby L, Persson F, Stenman G, Wängberg B, Stridsberg M, Nilsson O: A transplantable human medullary thyroid carcinoma (GOT2) - a model for tyrosine kinase-driven tumour growth (manuscript in preparation).
13. Westberg G, Ahlman H, Nilsson O, Illerskog A, Wängberg B: Secretory patterns of tryptophan metabolites in midgut carcinoid tumor cells. Neurochem Res 1997;22:977-983.
14. Öberg K, Ahlman H: Medical management of neuroendocrine gastrointestinal tumours; in Schwartz AE, Pertsemlidis D, Gagner M (eds): Endocrine Surgery. New York, Marcel Dekker, 2004, pp 685-696.
15. Martinsson P, Liminga G, Dhar S, de la Torre M, Lukinius A, Jonsson E, Bashir Hassan S, Binderap L, Kristensen J, Larsson R: Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells. Eur J Cancer 2001;37:260-267.
16. Abend M: Reasons to reconsider the significance of apoptosis for cancer therapy. Int J Radiat Biol 2003;79:927-941.
17. Nicotera P, Melino G: Regulation of the apoptosis-necrosis switch. Oncogene 2004;23:2757-2765.
18. Castedo M, Perfettini JL, Roumier T, Valent A, Raslova H, Yakushijin K, Home D, Feunteun J, Lenoir G, Medema R, Vainchenker W, Kroemer G: Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 2004;23:4362-4370.
19. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr: NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999;19:5923-5929.
20. Cheng Q, Lee HH, Li Y, Parks TP, Cheng G: Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-κB inhibition. Oncogene 2000;19:4936-4940.
21. Lövborg H, Martinsson P, Gullbo J, Ekelund S, Nygren P, Larsson R: Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells. Biochem Pharmacol 2002;63:1491-1498.